Evaluation of Dentifrice Formulations to Remineralize Enamel and Dentine Subsurface Lesions in a Double-Blind In-Situ Clinical Trial

NCT ID: NCT06140745

Last Updated: 2023-11-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-05

Study Completion Date

2021-02-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare the remineralization and demineralization inhibition potential of early subsurface carious lesions in enamel in situ after rinsing with five different aqueous slurries of toothpaste formulations. Percent remineralization (%R), i.e. the % change in ΔZ values relative to ΔZd, will be the primary outcome measure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Caries

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

0 ppm Fluoride Dentifrice 1

Group Type PLACEBO_COMPARATOR

0 ppm Fluoride Dentifrice 1

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design.

1100 ppm NaF Fluoride Dentifrice

Group Type ACTIVE_COMPARATOR

1100 ppm NaF Fluoride Dentifrice

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design.

1500 ppm NaMFP Fluoride Dentifrice

Group Type ACTIVE_COMPARATOR

1500 ppm NaMFP Fluoride Dentifrice

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design.

0 ppm Fluoride Dentifrice 2

Group Type SHAM_COMPARATOR

0 ppm Fluoride Dentifrice 2

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design.

0 ppm Fluoride Dentifrice 3

Group Type SHAM_COMPARATOR

0 ppm Fluoride Dentifrice 3

Intervention Type DRUG

Each subject will use this product during one of the five treatment periods in the crossover study design.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

0 ppm Fluoride Dentifrice 1

Each subject will use this product during one of the five treatment periods in the crossover study design.

Intervention Type DRUG

1100 ppm NaF Fluoride Dentifrice

Each subject will use this product during one of the five treatment periods in the crossover study design.

Intervention Type DRUG

1500 ppm NaMFP Fluoride Dentifrice

Each subject will use this product during one of the five treatment periods in the crossover study design.

Intervention Type DRUG

0 ppm Fluoride Dentifrice 2

Each subject will use this product during one of the five treatment periods in the crossover study design.

Intervention Type DRUG

0 ppm Fluoride Dentifrice 3

Each subject will use this product during one of the five treatment periods in the crossover study design.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be 18-75 years of age;
* Provide written informed consent prior to participation and be given a signed copy of the informed consent form;
* Be in good general health based on medical/dental history and oral exam;
* Have no history of adverse or allergic reactions to tin or tin-containing products;
* Agree not to participate in any other oral study for the study duration;
* Have a reasonable functional dentition as determined by the oral examiner and sufficient teeth to support the fabricated dental appliance;
* Be willing to participate in the study, able to follow the study directions, successfully tolerate/perform all study procedures, and willing to return for all specified visits at their appointed time;
* Be willing to refrain from using non-study dentifrice, mouth rinse, chewing gum, and other non-study oral care products during the study;
* Be willing to postpone all elective dental procedures until the study has been completed;
* Be willing to refrain from using calcium chews while using the test products;
* Be willing and able to refrain from wearing a nightguard (occlusal splint) for the entire course of the study (for nightguard wearers only).
* Ability to understand, and ability to read and sign, the informed consent form;
* Have at least 22 natural teeth;
* Have a gum-stimulated whole salivary flow rate ≥1.0 ml/minute and unstimulated whole salivary flow rate ≥ 0.2 ml/minute.
* Willingness to comply with all study procedures and be available for the duration of the study.

Exclusion Criteria

* Advanced periodontal disease, as characterized by purulent exudate, generalized mobility, and/or severe recession;
* Active treatment for periodontitis;
* A medical condition which requires premedication prior to dental visits/procedures;
* Untreated dental problems (e.g. cavities);
* Self-reported pregnancy or plans to become pregnant during the study;
* Existing dental work which prevents wearing of the appliance including orthodontic appliances or removable dentures;
* Chronic disease such as diabetes or use of medications that cause gum swelling;
* Any diseases or conditions (including sensitivity to dentifrice ingredients or a history of allergic or adverse reactions to tin or tin-containing products) that might interfere with examination procedures or the participant safely completing the study;
* Treatment with antibiotics or anti-inflammatory medicines in the month prior to starting the study;
* Use of drugs that may interact with the toothpaste slurries or which may affect salivary flow rate;
* History of health conditions requiring antibiotic coverage prior to dental treatment;
* Serious infectious disease;
* Any other medical or dental conditions deemed to put the health and wellbeing of the participant or research team at risk if the potential participant participated in the study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Procter and Gamble

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Melbourne

Melbourne, , Australia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2019176

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

In Situ Caries of Fluoride Toothpastes
NCT00708123 COMPLETED PHASE3